Displaying drugs 14851 - 14875 of 15568 in total
VIT-100
VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated...
Investigational
Talampicillin
Experimental
BTA798
BTA798 is an antiviral for the treatment of HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and Chronic Obstructive Pulmonary Disease.
Investigational
Matched Description: … HRV, the common cold virus, known to cause significant clinical complications in sufferers of Asthma and …
Nesolicaftor
Nesolicaftor (PTI-428) is under investigation in clinical trial NCT03258424 (Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy).
Investigational
Matched Description: … is under investigation in clinical trial NCT03258424 (Study Assessing PTI-428 Safety, Tolerability, and …
Ladostigil
Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment).
Investigational
Matched Description: … Ladostigil is under investigation in clinical trial NCT01429623 (A 3 Year Study to Evaluate the Safety and …
BEA-17
BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. It is under investigation for the treatment of glioblastoma.
Investigational
Matched Description: … BEA-17 is a small molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST. …
AZD 3355
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Investigational
Matched Description: … It is developed by AstraZeneca and is currently in phase I/II trials. …
AZD-4017
AZD-4017 is under investigation in clinical trial NCT01173471 (A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure).
Investigational
Matched Description: … investigation in clinical trial NCT01173471 (A Phase IIa Study to Assess the Tolerability, Safety, and …
Giripladib
Giripladib is under investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and Placebo In Subjects With Osteoarthritis Of The Knee).
Investigational
Matched Description: … investigation in clinical trial NCT00396955 (A Study Comparing 4 Dose Regimens of PLA-695, Naproxen, and …
PAS-004
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Description: … It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome. …
AZD-4818
AZD4818 has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Investigational
Didesmethylrocaglamide
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of ... being studied for use as chemotherapeutic agents in the treatment of various leukemias, lymphomas, and …
ATL-2502
ATL-2502(Colal-Pred) is an old drug (prednisolone metasulphobenzoate, a steroid) with a new delivery system that releases the medication only in the colon. Releasing the drug directly into the colon reduces the potential for significant side effects often experienced with steroid drugs. Colal-Pred is being studied for use in ulcerative colitis.
Investigational
Adomiparin
Investigational
Ravuconazole
Investigational
Tetraethylammonium
Tetraethylammonium is an experimental drug with no approved indication or marketed formulation. The only marketed drug containing tetraethylammonium was a combination drug called Fosglutamina B6, but this drug has now been discontinued. As an experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and tetraethylammonium bromide....
Experimental
Investigational
Matched Description: … voltage- activated potassium channels, and nicotinic acetylcholine receptors. ... experimental agent, tetraethylammonium is used in its salt forms such as tetraethylammonium chloride and ... still being investigated, but it is known that tetraethylammonium blocks autonomic ganglia, calcium- and …
3h-Indole-5,6-Diol
Experimental
Xylose-derived lactam oxime
Experimental
D-gluconhydroximo-1,5-lactam
Experimental
Hydrogenobyrinic acid
Experimental
Indirubin-5-sulphonate
Experimental
Siroheme
Experimental
2-Acetyl-Protoporphyrin Ix
Experimental
Displaying drugs 14851 - 14875 of 15568 in total